NasdaqGM - Nasdaq Real Time Price USD

Omeros Corporation (OMER)

3.1400 +0.0800 (+2.61%)
As of 3:08 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Cost of Revenue
--
--
--
902.0000
Gross Profit
--
--
--
72,911.0000
Operating Expense
164,903.0000
163,389.0000
173,617.0000
156,918.0000
Operating Income
-164,903.0000
-163,389.0000
-173,617.0000
-156,918.0000
Net Non Operating Interest Income Expense
-16,778.0000
-18,640.0000
-17,929.0000
-26,097.0000
Other Income Expense
--
--
1,740.0000
-13,374.0000
Pretax Income
-181,681.0000
-182,029.0000
-191,546.0000
-196,389.0000
Tax Provision
--
--
--
-23,256.0000
Net Income Common Stockholders
19,988.0000
47,417.0000
194,235.0000
-138,061.0000
Diluted NI Available to Com Stockholders
19,988.0000
47,417.0000
194,235.0000
-138,061.0000
Basic EPS
0.33
0.76
3.12
-2.41
Diluted EPS
0.33
0.76
3.12
-2.41
Basic Average Shares
62,821.6260
62,737.0910
62,344.1000
57,176.7430
Diluted Average Shares
62,821.6260
62,737.0910
62,344.1000
57,176.7430
Total Operating Income as Reported
-164,903.0000
-163,389.0000
-173,617.0000
-156,918.0000
Total Expenses
164,903.0000
163,389.0000
173,617.0000
156,918.0000
Net Income from Continuing & Discontinued Operation
19,988.0000
47,417.0000
194,235.0000
-138,061.0000
Normalized Income
-181,681.0000
-182,029.0000
-191,546.0000
-161,342.7228
Interest Income
14,906.0000
4,062.0000
1,740.0000
654.0000
Interest Expense
31,684.0000
22,702.0000
19,669.0000
26,751.0000
Net Interest Income
-16,778.0000
-18,640.0000
-17,929.0000
-26,097.0000
EBIT
-149,997.0000
-159,327.0000
-171,877.0000
-169,638.0000
EBITDA
-149,119.0000
-158,375.0000
-170,491.0000
-168,022.0000
Reconciled Cost of Revenue
--
--
--
902.0000
Reconciled Depreciation
878.0000
952.0000
1,386.0000
1,616.0000
Net Income from Continuing Operation Net Minority Interest
-181,681.0000
-182,029.0000
-191,546.0000
-173,133.0000
Total Unusual Items Excluding Goodwill
--
--
--
-13,374.0000
Total Unusual Items
--
--
--
-13,374.0000
Normalized EBITDA
-149,119.0000
-158,375.0000
-170,491.0000
-154,648.0000
Tax Rate for Calcs
--
--
--
0.0001
Tax Effect of Unusual Items
--
--
--
-1,583.7228
12/31/2020 - 10/8/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

REPL Replimune Group, Inc.
6.43
+4.55%
 
LYRA Lyra Therapeutics, Inc.
4.7900
-7.35%
 
MIRM Mirum Pharmaceuticals, Inc.
24.59
+0.41%
 
PHVS Pharvaris N.V.
23.89
+4.92%
 
BCRX BioCryst Pharmaceuticals, Inc.
4.1600
0.00%
 
IMCR Immunocore Holdings plc
57.78
-0.38%
 
ZVRA Zevra Therapeutics, Inc.
4.5300
+0.22%
 
RCUS Arcus Biosciences, Inc.
15.40
+4.55%
 
RGNX REGENXBIO Inc.
16.33
+1.68%
 
FDMT 4D Molecular Therapeutics, Inc.
23.34
-0.81%